secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-09-30T20:05:16+00:00
Accession:  0001493152-26-045100
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Lantern Pharma closes $4M registered direct offering with up to $8M total including warrants
--------------------------------------------------------------------------------

- Lantern Pharma sold 1,469,725 common shares at $1.09 and 2,200,000 pre-funded warrants at $1.0899 in a registered direct offering that closed September 30, 2026.
- In a concurrent private placement, Lantern issued warrants to purchase 3,669,725 shares at $1.09, exercisable only after stockholder approval and expiring five years after approval.
- Gross proceeds were approximately $4.0 million upfront, with up to $4 million more if the warrants are fully exercised; Rodman & Renshaw acted as placement agent.
- Lantern paid Rodman & Renshaw a 7% cash fee, issued placement agent warrants for 5% of shares sold at $1.3625 per share, and will pay a 3% cash fee on warrant exercises.
- The company must seek stockholder approval within 90 days of September 28, 2026 and intends to use net proceeds for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226045100/0001493152-26-045100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226045100/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer